• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 4, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Hubrecht Organoid Technology and CrownBio announce a strategic partnership

Bioengineer by Bioengineer
March 27, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Utrecht, March 26, 2019 – Hubrecht Organoid Technology (HUB) and JSR Corporation the parent company, of Crown Bioscience, entered into a strategic partnership to provide preclinical oncology drug development and validation services using HUB Organoid Technology. As part of the agreement CrownBio, a wholly-owned subsidiary of JSR Corporation will expand its European presence by opening a new organoid-focused operational site in Utrecht, Netherlands.

The partnership brings together HUB’s leading organoid technology platform and CrownBio’s global reach and preclinical service expertise to create an unparalleled translational platform to accelerate drug development and validation. HUB and CrownBio will establish a collaborative research program to accelerate further development of organoid technology. By opening a new site in Utrecht, Netherlands, CrownBio will help to cement Utrecht’s position as the global center of organoid technology research.

In recent years, novel organoid technology has firmly established itself as a paradigm shifting technology in drug development. This collaboration allows HUB and CrownBio to meet increasing demand from the industry for clinically relevant preclinical models.

“We are delighted to increase access to HUB organoid technology for researchers worldwide through CrownBio’s global reach and preclinical service expertise,” said Dr. Robert Vries, Executive Director of HUB. “Our partnership with CrownBio equips the drug development community with powerful new translational tools to guide the creation of novel and improved treatments for cancer.”

“This agreement is a pivotal moment in our growth and the evolution of the company,” said Dr. Jean-Pierre Wery, CEO of CrownBio. “The partnership positions CrownBio at the forefront of global preclinical research.”

###

About HUB

HUB exploits the pioneering work of Prof. Hans Clevers, who discovered methods to grow stem cell-derived human ‘mini-organs’ (HUB Organoids). Organoid Technology enables the generation of in-vitro models of any epithelial disease from any patient. HUB Organoids mimic organ functionality and are considered to be a clinically relevant model for human diseases such as Cystic Fibrosis, oncology and toxicology. HUB Organoids perform as “Patients in the Lab” and allow a better understanding of tumor heterogeneity and drug response. HUB has established a “Living Biobank” that links patient-specific genetic and phenotypic information to pre-clinical drug discovery, compounds validation and clinical drug-responsiveness. As a drug development tool, HUB organoids can efficiently identify novel therapeutic targets, provide drug efficacy, safety and mechanistical data.

HUB offers licenses to its patented HUB Organoid Technology for drug-screening and access to Organoids in the HUB biobanks for pre-clinical drug discovery and validation. In addition, HUB is performing clinical studies to validate the technologies used as a companion diagnostic. More info at: http://www.hub4organoids.eu.

About Crown Bioscience Inc.

CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an
extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates. For more information about CrownBio’s translational oncology platforms visit https://www.crownbio.com.

For further inquiry into this topic, please contact HUB’s Managing Director, Dr. Rob Vries ([email protected]) or HUB’s Head Business Development, Dr. Bahar Ramezanpour ([email protected])

Media Contact
Dr. Robert Vries
[email protected]
http://hub4organoids.eu/988-2/

Tags: cancerCollaborationGroup OrganizationHealth CareMedicine/Health
Share13Tweet8Share2ShareShareShare2

Related Posts

Nitric Oxide Drives Metabolic Shift in Macrophages

Nitric Oxide Drives Metabolic Shift in Macrophages

August 4, 2025
Alzheimer’s Transcriptional Landscape Mapped in Human Microglia

Alzheimer’s Transcriptional Landscape Mapped in Human Microglia

August 4, 2025

Psychedelics and Non-Hallucinogenic Analogs Activate the Same Receptor—But Only to a Certain Extent

August 4, 2025

Cellular Senescence: Key Aging and Disease Mechanisms

August 4, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    57 shares
    Share 23 Tweet 14
  • Predicting Colorectal Cancer Using Lifestyle Factors

    45 shares
    Share 18 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

AI Models Reveal Microplastics in Neuse River Basin

Gratitude vs. Behavioral Activation in Breast Cancer

Nitric Oxide Drives Metabolic Shift in Macrophages

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.